177 related articles for article (PubMed ID: 34929499)
1. Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model.
Chai LF; Hardaway JC; Heatherton KR; O'Connell KP; LaPorte JP; Guha P; Lopes MC; Rabinowitz BA; Jaroch D; Cox BF; Knight R; Katz SC
J Surg Res; 2022 Apr; 272():37-50. PubMed ID: 34929499
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
3. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
4. Locoregional delivery of CAR-T cells in the clinic.
Sagnella SM; White AL; Yeo D; Saxena P; van Zandwijk N; Rasko JEJ
Pharmacol Res; 2022 Aug; 182():106329. PubMed ID: 35772645
[TBL] [Abstract][Full Text] [Related]
5. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
7. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
8. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
9. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
Qian S; Chen J; Zhao Y; Zhu X; Dai D; Qin L; Hong J; Xu Y; Yang Z; Li Y; Guijo I; Jiménez-Galanes S; Guadalajara H; García-Arranz M; García-Olmo D; Shen J; Villarejo-Campos P; Qian C
Cytotherapy; 2024 Feb; 26(2):113-125. PubMed ID: 37999667
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in CAR-T cells therapy for colorectal cancer.
Qin X; Wu F; Chen C; Li Q
Front Immunol; 2022; 13():904137. PubMed ID: 36238297
[TBL] [Abstract][Full Text] [Related]
13. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
14. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S; Villarejo-Campos P; Guijo I; Hernández-Villafranca S; García-Olmo D; González-Soares S; Guadalajara H; Jiménez-Galanes S; Qian C
Front Immunol; 2022; 13():841425. PubMed ID: 35401510
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
16. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometry detection and quantification of CAR T cells into solid tumors.
Tokarew NJA; Gosálvez JS; Nottebrock A; Briukhovestka D; Endres S; Cadilha BL; Kobold S
Methods Cell Biol; 2022; 167():99-122. PubMed ID: 35153001
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
19. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
20. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.
Katz SC; Moody AE; Guha P; Hardaway JC; Prince E; LaPorte J; Stancu M; Slansky JE; Jordan KR; Schulick RD; Knight R; Saied A; Armenio V; Junghans RP
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
